Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 22, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)

Autolus Therapeutics announces acceptance of BLA for obe-cel as a potential treatment for relapsed/refractory adult ALL